Heparin protects basic and acidic FGF from inactivation
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The ability of heparin or that of hexuronyl hexosaminoglygan sulfate (HHS‐4) to protect basic or acidic fibroblast growth factor (FGF) from acid or heat inactivation has been analyzed. Both freshly prepared basic and acidic FGF stimulate the growth of baby hamster kidney (BHK‐21) cells exposed to medium supplemented with transferrin and insulin. Freshly prepared basic FGF was 10 fold more potent than acidic FGF. The addition of heparin to the medium decreased the potency of basic FGF while it potentiated that of acidic FGF. Upon storage of FGF at −80°C, a decline in potency of both basic and acidic FGF was observed. Heparin, when added to the medium, potentiated their activities, which became similar to that of freshly prepared basic FGF. In order to test whether heparin could protect basic or acidic FGF from inactivation, both mitogens were exposed to acid conditions (1% trifluoroacetic acid, pH 1.08, 2 h) or heat (65°C, 5 min) which inactivate basic or acidic FGF. When exposed to such treatment in the presence of heparin or HHS‐4, basic and acidic FGF retained their potency. The effect of heparin and HHS‐4 on the bioactivity of basic and acidic FGF is truly of a protective nature, since they had no effect when added after inactivation of the mitogens. Potentiation of the bioactivity of the protected mitogens or of the inactivated one could only be observed when cells were exposed to high heparin or HHS‐4 concentrations. This indicates that heparin and HHS‐4, in addition to protecting FGF from inactivation, also acts at another locus, as yet unidentified.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Binding of FGF-2 to heparan sulfate also imparts stability to the growth factor.”
From Interactions between extracellular matrix and growth factors in wound healing (2009) · cites this paper as [40]
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Markwell, M. A. K., Haas, S. M., Bieber, L. L., & Tolbert, N. E. (1978) · Analytical Biochemistry · doi:10.1016/0003-2697(78)90586-9 · Cited by 6,458
Epidermal Growth Factor and a New Derivative
Savage, C. R., & Cohen, S. (1972) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)44568-7 · Cited by 1,208
Heparin Affinity: Purification of a Tumor-Derived Capillary Endothelial Cell Growth Factor
Shing, Y., Folkman, J., Sullivan, R., Butterfield, C., Murray, J., & Klagsbrun, M. (1984) · Science · doi:10.1126/science.6199844 · Cited by 933
Human Endothelial Cells: Use of Heparin in Cloning and Long-Term Serial Cultivation
Thornton, S. C., Mueller, S. N., & Levine, E. M. (1983) · Science · doi:10.1126/science.6635659 · Cited by 793
Esch, F., Baird, A., Ling, N., Ueno, N., Hill, F., Denoroy, L., Klepper, R., Gospodarowicz, D., Böhlen, P., & Guillemin, R. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.19.6507 · Cited by 693
Self-citationCultured endothelial cells produce heparinlike inhibitor of smooth muscle cell growth
Castellot, J., Addonizio, M., Rosenberg, R., & Karnovsky, M. (1981) · The Journal of Cell Biology · doi:10.1083/jcb.90.2.372 · Cited by 679
Gospodarowicz, D., Cheng, J., Lui, G. M., Baird, A., & Böhlent, P. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.22.6963 · Cited by 613
Self-citationPurification of a fibroblast growth factor from bovine pituitary.
Gospodarowicz, D. (1975) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)41631-1 · Cited by 591
Self-citationPurification of the fibroblast growth factor activity from bovine brain.
Gospodarowicz, D., Bialecki, H., & Greenburg, G. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34863-9 · Cited by 492
Self-citation
Research works printed but not linked: 1
- Gospodarowicz D., 1986, Methods in Enzymology
Cited by
(1997) · Obesity Surgery · doi:10.1381/096089297765555359 · Cited by 3,916
Folkman, J., & Klagsbrun, M. (1987) · Science · doi:10.1126/science.2432664 · Cited by 3,491
Folkman, J., & Shing, Y. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49853-0 · Cited by 2,654
Yayon, A., Klagsbrun, M., Esko, J. D., Leder, P., & Ornitz, D. M. (1991) · Cell · doi:10.1016/0092-8674(91)90512-w · Cited by 2,440
Requirement of Heparan Sulfate for bFGF-Mediated Fibroblast Growth and Myoblast Differentiation
Rapraeger, A. C., Krufka, A., & Olwin, B. B. (1991) · Science · doi:10.1126/science.1646484 · Cited by 1,508
Fibroblast growth factors, their receptors and signaling
Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070165 · Cited by 1,332
“Early studies of the binding of FGF-1 and -2 to heparin showed that this interaction protected the growth factors from acid and heat (Gospodarowicz & Cheng 1986), to which they are extremely sensitive, and from degradation by aprotinin-sensitive proteases (Damonet al. 1989).”
BackgroundStructural Characterization and Biological Functions of Fibroblast Growth Factor
GOSPODAROWICZ, D., FERRARA, N., SCHWEIGERER, L., & NEUFELD, G. (1987) · Endocrine Reviews · doi:10.1210/edrv-8-2-95 · Cited by 1,273
Self-citationThe Fgf Family of Growth Factors and Oncogenes
(1992) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60305-x · Cited by 1,145
Houck, K. A., Leung, D. W., Rowland, A. M., Winer, J., & Ferrara, N. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35712-0 · Cited by 1,127
Interactions between extracellular matrix and growth factors in wound healing
Schultz, G. S., & Wysocki, A. (2009) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2009.00466.x · Cited by 1,126
“Binding of FGF-2 to heparan sulfate also imparts stability to the growth factor.(40) In fact, active FGF-2–heparan sulfate complexes can be generated through proteolysis, and this release can be positively and negatively regulated by factors that affect cellular proteolytic activity.”
BackgroundVlodavsky, I., Folkman, J., Sullivan, R., Fridman, R., Ishai-Michaeli, R., Sasse, J., & Klagsbrun, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.8.2292 · Cited by 1,032
Recent developments in the cell biology of basic fibroblast growth factor.
Rifkin, D. B., & Moscatelli, D. (1989) · The Journal of cell biology · doi:10.1083/jcb.109.1.1 · Cited by 1,021
Folkman, J., Klagsbrun, M., Sasse, J., Wadzinski, M., Ingber, D. E., & Vlodavsky, I. (1988) · PubMed · Cited by 969
Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis
Roberts, R., Gallagher, J., Spooncer, E., Alien, T. D., Bloomfield, F., & Dexter, T. M. (1988) · Nature · doi:10.1038/332376a0 · Cited by 807
Saksela, O., Moscatelli, D., Sommer, A., & Rifkin, D. B. (1988) · The Journal of cell biology · doi:10.1083/jcb.107.2.743 · Cited by 804
“Complex formation protects both acidic fibroblast growth factors and bFGFs from heat and acid inactivation ( 10 ).”
BackgroundInorganic Polyphosphate: Essential for Growth and Survival
Rao, N. N., Gómez-García, M. R., & Kornberg, A. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.083007.093039 · Cited by 794
Structural basis for fibroblast growth factor receptor activation
Mohammadi, M., Olsen, S. K., & Ibrahimi, O. A. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.008 · Cited by 735
“Heparin/HS was proposed to: (i) stabilize and protect FGFs from thermal, proteolytic, or pH-dependent degradation [77,78], (ii) function as storage reservoirs where FGF can be liberated for interaction with FGFR [79–83], or (iii) facilitate FGF– FGFR encounters by limiting the dimensionality of FGF ligand [84].”
BackgroundMaternal immune activation and neuroinflammation in human neurodevelopmental disorders
Han, V. X., Patel, S., Jones, H. F., & Dale, R. C. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00530-8 · Cited by 683
Stabilization of proteins encapsulated in injectable poly (lactide- co-glycolide)
Zhu, G., Mallery, S. R., & Schwendeman, S. P. (2000) · Nature Biotechnology · doi:10.1038/71916 · Cited by 609
“Basic fibroblast growth factor binds heparin, and when unbound, loses activity rapidl”
BackgroundTumor interactions with the vasculature: angiogenesis and tumor metastasis
Blood, C. (1990) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(90)90014-r · Cited by 593
Arakawa, Y., Sendtner, M., & Thoenen, H. (1990) · The Journal of Neuroscience · doi:10.1523/jneurosci.10-11-03507.1990 · Cited by 582
“The survival activity of acidic FGF could be increased when the cultures were supplemented with heparin, which prevents inactivation of acidic FGF (Gospodarowicz and Cheng, 1986).”
BackgroundFibroblast Growth Factor Signaling during Early Vertebrate Development
Böttcher, R. T., & Niehrs, C. (2005) · Endocrine Reviews · doi:10.1210/er.2003-0040 · Cited by 540
“Other than promoting FGF binding to its receptors, HSPGs protect the FGFs from thermal denaturation and proteolysis (176).”
BackgroundSavagner, P., Yamada, K. M., & Thiery, J. P. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.6.1403 · Cited by 520
Gitay-Goren, H., Soker, S., Vlodavsky, I., & Neufeld, G. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42666-x · Cited by 490
Mattson, M., Murrain, M., Guthrie, P., & Kater, S. (1989) · The Journal of Neuroscience · doi:10.1523/jneurosci.09-11-03728.1989 · Cited by 480
“The latter finding is consistent with previous reports which indicated that the biological activity of FGF decreases with time in culture (Gospodarowicz and Cheung, 1986; Gospodarowicz et al., 1986; Morrison et al., 1986; Walicke et al., 1986).”
ResultZhuang, G., Wu, X., Jiang, Z., Kasman, I., Yao, J., Guan, Y., Oeh, J., Modrusan, Z., Bais, C., Sampath, D., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.183 · Cited by 471
“Also, other studies have shown that, once bound to heparin, growth factors may become much more stable and resistant to degradation induced by various agents (Gospodarowicz and Cheng, 1986).”
Gospodarowicz, D., Neufeld, G., & Schweigerer, L. (1986) · Cell Differentiation · doi:10.1016/0045-6039(86)90021-7 · Cited by 466
Self-citationLahiji, A., Sohrabi, A., Hungerford, D. S., & Frondoza, C. G. (2000) · Journal of Biomedical Materials Research · doi:10.1002/1097-4636(20000915)51:4<586::aid-jbm6>3.0.co;2-s · Cited by 464
Chang, H. C., Samaniego, F., Nair, B. C., Buonaguro, L., & Ensoli, B. (1997) · AIDS · doi:10.1097/00002030-199712000-00006 · Cited by 442
“It has also been demonstrated that secreted HSPG or heparin bind extracellular bFGF and protect it from proteolytic degradation [48,50].”
BackgroundPerets, A., Baruch, Y., Weisbuch, F., Shoshany, G., Neufeld, G., & Cohen, S. (2003) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.10542 · Cited by 439
“Its binding to heparin induces a conformational change in the bFGF molecule resulting in an increased resistance against thermal denaturation and enzymatic degradation, and a reduced activation at acidic pH.(24,25) Our studies reveal that the entrapment of bFGF-heparin, 1:1 weight ratio, enabled the stabilization of b…”
BackgroundMicroglia-organized scar-free spinal cord repair in neonatal mice
Li, Y., He, X., Kawaguchi, R., Zhang, Y., Wang, Q., Monavarfeshani, A., Yang, Z., Chen, B., Shi, Z., Meng, H., et al. (2020) · Nature · doi:10.1038/s41586-020-2795-6 · Cited by 429
N.m.r. and molecular-modelling studies of the solution conformation of heparin
Mulloy, B., Forster, M. J., Jones, C., & Davies, D. B. (1993) · Biochemical Journal · doi:10.1042/bj2930849 · Cited by 410
Theocharis, A. D., Skandalis, S. S., Tzanakakis, G. N., & Karamanos, N. K. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07800.x · Cited by 403
Interactions of formulation excipients with proteins in solution and in the dried state
Ohtake, S., Kita, Y., & Arakawa, T. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.011 · Cited by 398
“KGF is also characterized by its ability to bind heparin and poly-anions, which results in its stabilization [64–69].”
BackgroundThe anti-inflammatory effects of heparin and related compounds
Young, E. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2006.10.026 · Cited by 390
“This binding protects bFGF from heat and acid-mediated inactivation [45] as well as nonenzymic glycosylation [44].”
BackgroundGrowth factors improve muscle healing in vivo
Menetrey, J., Kasemkijwattana, C., Day, C. S., Bosch, P., Vogt, M., Fu, F. H., Moreland, M. S., & Huard, J. (2000) · The Journal of Bone and Joint Surgery. British volume · doi:10.1302/0301-620x.82b1.0820131 · Cited by 390
Enzymatic Degradation of GlycosaminogIycans
Ernst, S., Langer, R., Cooney, C. L., & Sasisekharan, R. (1995) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239509083490 · Cited by 387
Perineuronal nets — a specialized form of extracellular matrix in the adult nervous system
Celio, M. R., & Blumcke, I. (1994) · Brain Research Reviews · doi:10.1016/0165-0173(94)90006-x · Cited by 385
Baird, A., & Böhlen, P. (1991) · Springer eBooks · doi:10.1007/978-1-4612-3210-0_7 · Cited by 381
Murakami, S., Kan, M., McKeehan, W. L., & de Crombrugghe, B. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.3.1113 · Cited by 377
Controlled and modulated release of basic fibroblast growth factor
Edelman, E. R., Mathiowitz, E., Langer, R., & Klagsbrun, M. (1991) · Biomaterials · doi:10.1016/0142-9612(91)90107-l · Cited by 363
Raines, E. W., Lane, T. F., Iruela-Arispe, M. L., Ross, R., & Sage, E. H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.4.1281 · Cited by 362
Gomez-Pinilla, F., Lee, J., & Cotman, C. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-01-00345.1992 · Cited by 361
The fibroblast growth factor family: Structural and biological properties
Klagsbrun, M. (1989) · Progress in Growth Factor Research · doi:10.1016/0955-2235(89)90012-4 · Cited by 361
Bioactive Nanofibers: Synergistic Effects of Nanotopography and Chemical Signaling on Cell Guidance
Patel, S., Kurpinski, K., Quigley, R., Gao, H., Hsiao, B. S., Poo, M.-M., & Li, S. (2007) · Nano Letters · doi:10.1021/nl071182z · Cited by 361
Mori, T., Okumura, M., Matsuura, M., Ueno, K., Tokura, S., Okamoto, Y., Minami, S., & Fujinaga, T. (1997) · Biomaterials · doi:10.1016/s0142-9612(97)00017-3 · Cited by 353
In vitro and in vivo interactions of cells with biomaterials
Ziats, N. P., Miller, K. M., & Anderson, J. M. (1988) · Biomaterials · doi:10.1016/0142-9612(88)90063-4 · Cited by 350
Heparin-functionalized polymeric biomaterials in tissue engineering and drug delivery applications
Liang, Y., & Kiick, K. L. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.07.031 · Cited by 349
“These interactions in many cases serve to stabilize proteins or increase their affinity for cell receptors [4]; such stabilization by heparin of the growth factors fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) has thus been employed in the design of materials as engineered scaffolds for…”
MethodBeyond the neuron–cellular interactions early in Alzheimer disease pathogenesis
Henstridge, C. M., Hyman, B. T., & Spires-Jones, T. L. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0113-1 · Cited by 348
Baffour, R., Berman, J., Garb, J. L., Rhee, S. W., Kaufman, J., & Friedmann, P. (1992) · Journal of Vascular Surgery · doi:10.1016/0741-5214(92)90106-i · Cited by 324
Freeman, I., Kedem, A., & Cohen, S. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.04.025 · Cited by 323
“It is likely that the equilibrium binding of bFGF to alginatesulfate prolongs the factor activity, similar to the stabilizing effect when it is bound to heparin [26,27].”
BackgroundQu, Z., Liebler, J. M., Powers, M. R., Galey, T., Ahmadi, P., Huang, X., Ansel, J. C., Butterfield, J. H., Planck, S. R., & Rosenbaum, J. T. (1995) · PubMed Central · Cited by 322
Stowell, R. D., Sipe, G. O., Dawes, R. P., Batchelor, H. N., Lordy, K. A., Whitelaw, B. S., Stoessel, M. B., Bidlack, J. M., Brown, E., Sur, M., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0514-0 · Cited by 321
Receptor- and heparin-binding domains of basic fibroblast growth factor.
Baird, A., Schubert, D., Ling, N., & Guillemin, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.7.2324 · Cited by 320
Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts
Cairns, J. A., & Walls, A. F. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119290 · Cited by 318
Pike, D. B., Cai, S., Pomraning, K. R., Firpo, M. A., Fisher, R. J., Shu, X. Z., Prestwich, G. D., & Peattie, R. A. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.05.018 · Cited by 316
“Interactions occur in part by shape recognition, but primarily as electrostatic attractions between N- and O-sulfated residues of heparin and the lysine and arginine residues of the GF [11-12].”
BackgroundSommer, A., & Rifkin, D. B. (1989) · Journal of Cellular Physiology · doi:10.1002/jcp.1041380129 · Cited by 304
Thompson, L. D., Pantoliano, M. W., & Springer, B. A. (1994) · Biochemistry · doi:10.1021/bi00179a006 · Cited by 302
Polysaccharide‐modified synthetic polymeric biomaterials
Baldwin, A. D., & Kiick, K. L. (2010) · Peptide Science · doi:10.1002/bip.21334 · Cited by 287
Vlodavsky, I., Miao, H.-Q., Medalion, B., Danagher, P., & Ron, D. (1996) · Cancer and Metastasis Reviews · doi:10.1007/bf00437470 · Cited by 286
“Since heparin and HS protect FGFs from inactivation by heat and oxidation [13], this protective effect could account for some of the opposing conclusions in experiments designed to assess the importance of heparin/HS in FGF-receptor binding.”
Three-dimensional structure of human basic fibroblast growth factor.
Eriksson, A. E., Cousens, L. S., Weaver, L. H., & Matthews, B. W. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.8.3441 · Cited by 284
Injectable biodegradable hydrogels: progress and challenges
Bae, K. H., Wang, L.-S., & Kurisawa, M. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb20940g · Cited by 283
Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism?
Vlodavsky, I., Bar-Shavit, R., Ishar-Michael, R., Bashkin, P., & Fuks, Z. (1991) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(91)90102-2 · Cited by 283
Chemical Synthesis of Glycosaminoglycans
Mende, M., Bednarek, C., Wawryszyn, M., Sauter, P., Biskup, M. B., Schepers, U., & Bräse, S. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00010 · Cited by 277
Effects of growth factors in vivo. I. Cell ingrowth into porous subcutaneous chambers.
Sprugel, K. H., McPherson, J. M., Clowes, A. W., & Ross, R. (1987) · PubMed Central · Cited by 275
Moscatelli, D. (1988) · The Journal of cell biology · doi:10.1083/jcb.107.2.753 · Cited by 272
Kweon, D., Song, S.-B., & Park, Y.-Y. (2003) · Biomaterials · doi:10.1016/s0142-9612(02)00566-5 · Cited by 265
Roghani, M., Mansukhani, A., Dell'Era, P., Bellosta, P., Basilico, C., Rifkin, D. B., & Moscatelli, D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41730-3 · Cited by 261
The Elusive Functions of Proteoglycans
Lander, A. D., & Selleck, S. B. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.148.2.227 · Cited by 260
“, 1984; Moscatelli, 1987), most early studies in this area concluded that HSPGs play no direct role in FGF–receptor interactions and, instead, relegated HS to the job of protecting FGFs from denaturation or proteolysis, or sequestering FGFs in the extracellular matrix (Gospodarowicz and Cheng, 1986; Moscatelli, 1987,…”
BackgroundZhang, J. D., Cousens, L. S., Barr, P. J., & Sprang, S. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.8.3446 · Cited by 250
Vlodavsky, I., Korner, G., Ishai-Michaeli, R., Bashkin, P., Bar-Shavit, R., & Fuks, Z. (1990) · CANCER AND METASTASIS REVIEW · doi:10.1007/bf00046361 · Cited by 250
“the FGF prototypes and heparin was found to protect these polypeptides from proteolytic modification and inactivation [37, 38].”
BackgroundInnate immunity at the crossroads of healthy brain maturation and neurodevelopmental disorders
Zengeler, K. E., & Lukens, J. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00487-7 · Cited by 246
Edelman, E. R., Nugent, M. A., Smith, L. T., & Karnovsky, M. J. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115607 · Cited by 245
Flaumenhaft, R., Moscatelli, D., & Rifkin, D. B. (1990) · The Journal of cell biology · doi:10.1083/jcb.111.4.1651 · Cited by 244
“…been studied and proposed to be of biological significance is the interaction between bFGF and heparin (Klagsburn and Shing, 1985; Gospodarowicz and Cheng, 1986; Saksela et al., 1988; Sommer and Rifkin, 1989; Saksela and Rifkin, 1990; Uhlrich et al., 1986). bFGF was initially purified using…”
MethodMaterials for protein delivery in tissue engineering
Baldwin, S. P., & Mark Saltzman, W. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00021-0 · Cited by 243
Aebischer, P., Salessiotis, A. N., & Winn, S. R. (1989) · Journal of Neuroscience Research · doi:10.1002/jnr.490230306 · Cited by 243
Wissink, M. J. B., Beernink, R., Poot, A. A., Engbers, G. H. M., Beugeling, T., van Aken, W. G., & Feijen, J. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00145-5 · Cited by 238
Olwin, B. B., & Rapraeger, A. (1992) · The Journal of cell biology · doi:10.1083/jcb.118.3.631 · Cited by 238
Nugent, M. A., & Edelman, E. R. (1992) · Biochemistry · doi:10.1021/bi00152a026 · Cited by 236
Flaumenhaft, R., Moscatelli, D., Saksela, O., & Rifkin, D. B. (1989) · Journal of Cellular Physiology · doi:10.1002/jcp.1041400110 · Cited by 228
Klagsbrun, M., & Edelman, E. R. (1989) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.9.3.269 · Cited by 227
Recent insights into coronary collateral circulation.
Sasayama, S., & Fujita, M. (1992) · Circulation · doi:10.1161/01.cir.85.3.1197 · Cited by 227
Human endometrial angiogenesis
Gargett, C. E., & Rogers, P. A. (2001) · Reproduction · doi:10.1530/rep.0.1210181 · Cited by 226
Bioactive factor delivery strategies from engineered polymer hydrogels for therapeutic medicine
Nguyen, M. K., & Alsberg, E. (2014) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2013.12.001 · Cited by 226
“1n), a highly sulfated anionic glycosaminoglycan (GAG) found in the extracellular matrix (ECM), can bind to a variety of proteins with high affinity via electrostatic interactions between N- and O-sulfated residues of HEP and the lysine and arginine residues of GFs [240,241].”
Control of Angiogenesis by Heparin and Other Sulfated Polysaccharides
Folkman, J., & Shing, Y. (1992) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4899-2444-5_34 · Cited by 224
Fibroblast growth factors and their receptors
Galzie, Z., Kinsella, A. R., & Smith, J. A. (1997) · Biochemistry and Cell Biology · doi:10.1139/bcb-75-6-669 · Cited by 214
“denaturation (Gospodarowicz and Chen 1986).”
Pieper, J. S., Hafmans, T., van Wachem, P. B., van Luyn, M. J. A., Brouwer, L. A., Veerkamp, J. H., & van Kuppevelt, T. H. (2002) · Journal of Biomedical Materials Research · doi:10.1002/jbm.10267 · Cited by 212
Mattson, M. P., & Rychlik, B. (1990) · International Journal of Developmental Neuroscience · doi:10.1016/0736-5748(90)90073-b · Cited by 209
Endothelial cell culture: protocol to obtain and cultivate human umbilical endothelial cells
Marin, V., Kaplanski, G., Grès, S., Farnarier, C., & Bongrand, P. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(01)00408-2 · Cited by 208
Vallés, A. M., Boyer, B., Badet, J., Tucker, G. C., Barritault, D., & Thiery, J. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.3.1124 · Cited by 207
Goretzki, L., Burg, M. A., Grako, K. A., & Stallcup, W. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.16831 · Cited by 206
A heparin-mimicking polymer conjugate stabilizes basic fibroblast growth factor
Nguyen, T. H., Kim, S.-H., Decker, C. G., Wong, D. Y., Loo, J. A., & Maynard, H. D. (2013) · Nature Chemistry · doi:10.1038/nchem.1573 · Cited by 206
Ishai-Michaeli, R., Eldor, A., & Vlodavsky, I. (1990) · Cell Regulation · doi:10.1091/mbc.1.11.833 · Cited by 206
Bauters, C., Asahara, T., Zheng, L. P., Takeshita, S., Bunting, S., Ferrara, N., Symes, J. F., & Isner, J. M. (1995) · Journal of Vascular Surgery · doi:10.1016/s0741-5214(95)70272-5 · Cited by 205
Implications of Insulin-Like Growth Factor-1 in Skeletal Muscle and Various Diseases
Ahmad, S. S., Ahmad, K., Lee, E. J., Lee, Y.-H., & Choi, I. (2020) · Cells · doi:10.3390/cells9081773 · Cited by 202
“Specifically, heparin has been shown to prevent the deactivation of GFs [21,24], enhance their interactions with receptors [25], increase GF loading into delivery vehicles [26], and facilitate the longterms releases of GFs [26,27].”
BackgroundWiedemann, P. (1992) · Survey of Ophthalmology · doi:10.1016/0039-6257(92)90115-a · Cited by 199
D'Angelo, G., Lee, H., & Weiner, R. I. (1997) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19971201)67:3<353::aid-jcb7>3.0.co;2-v · Cited by 195
Roghani, M., & Moscatelli, D. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41648-1 · Cited by 194
Gitay-Goren, H., Cohen, T., Tessler, S., Soker, S., Gengrinovitch, S., Rockwell, P., Klagsbrun, M., Levi, B.-Z., & Neufeld, G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.10.5519 · Cited by 194
Rogelj, S., Klagsbrun, M., Atzmon, R., Kurokawa, M., Haimovitz, A., Fuks, Z., & Vlodavsky, I. (1989) · The Journal of cell biology · doi:10.1083/jcb.109.2.823 · Cited by 189
“Although this result does not exclude the existence in ECM of growth factors and mitogenic matrix constitutents other than bFGF, it may well be that the matrix is more effective than soluble bFGF due to stabilization and protection of the ECM-bound bFGF ( 11 ).”
Background
Metadata
- Authors
- Gospodarowicz, D., & Cheng, J.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Gospodarowicz, D.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 1986-09
- Volume
- 128
- Issue
- 3
- Pages
- 475-484
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W1972855766
- Cited by
- 853
- References
- 30
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 8 · 2023: 6 · 2022: 11 · 2021: 13 · 2020: 10 · 2019: 12 · 2018: 9 · 2017: 8 · 2016: 18 · 2015: 10 · 2014: 9 · 2013: 11 · 2012: 22
- FWCI
- 14.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Cellular Physiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (HL 20197)
- National Eye Institute (EY02186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- heparin, basic fibroblast growth factor, acidic fibroblast growth factor, acid inactivation, thermal inactivation
- MeSH terms
- Animals, Cell Division, Cell Line, Fibroblast Growth Factors, Fibroblasts, Glycosaminoglycans, Cricetinae, Hot Temperature, Heparin, Hydrogen-Ion Concentration, Insulin, Kidney, Mesocricetus, Transferrin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.